Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $77.64 in the prior trading day, PTC Therapeutics Inc (NASDAQ: PTCT) closed at $76.19, down -1.87%. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 0.67 million shares were traded. PTCT stock price reached its highest trading level at $77.93 during the session, while it also had its lowest trading level at $75.58.
Ratios:
Our goal is to gain a better understanding of PTCT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.67. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 2.32.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $73.
On June 17, 2025, Truist started tracking the stock assigning a Buy rating and target price of $80.Truist initiated its Buy rating on June 17, 2025, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 30 ’25 when Klein Matthew B. bought 8,089 shares for $76.64 per share.
Pauwels Eric sold 20,508 shares of PTCT for $1,584,350 on Dec 19 ’25. The CHIEF BUSINESS OFFICER now owns 70,373 shares after completing the transaction at $77.26 per share. On Dec 17 ’25, another insider, Pauwels Eric, who serves as the CHIEF BUSINESS OFFICER of the company, sold 40,290 shares for $75.43 each. As a result, the insider received 3,038,924 and left with 70,373 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 6117166080 and an Enterprise Value of 6901902848. As of this moment, PTC’s Price-to-Earnings (P/E) ratio for their current fiscal year is 8.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.44. Its current Enterprise Value per Revenue stands at 3.879 whereas that against EBITDA is 7.228.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.48, which has changed by 0.6922406 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $87.50, while it has fallen to a 52-week low of $35.95. The 50-Day Moving Average of the stock is 2.24%, while the 200-Day Moving Average is calculated to be 32.92%.
Shares Statistics:
The stock has traded on average 1.51M shares per day over the past 3-months and 1178130 shares per day over the last 10 days, according to various share statistics. A total of 79.93M shares are outstanding, with a floating share count of 77.16M. Insiders hold about 3.90% of the company’s shares, while institutions hold 103.02% stake in the company. Shares short for PTCT as of 1765756800 were 11442932 with a Short Ratio of 7.57, compared to 1763078400 on 9418915. Therefore, it implies a Short% of Shares Outstanding of 11442932 and a Short% of Float of 16.350001.
Earnings Estimates
The market rating for PTC Therapeutics Inc (PTCT) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$1.09, with high estimates of -$1.03 and low estimates of -$1.14.
Analysts are recommending an EPS of between $10.66 and $5.52 for the fiscal current year, implying an average EPS of $8.82. EPS for the following year is -$0.84, with 6.0 analysts recommending between $1.25 and -$3.48.
Revenue Estimates
12 analysts predict $237.29M in revenue for. The current quarter. It ranges from a high estimate of $385.47M to a low estimate of $167.67M. As of. The current estimate, PTC Therapeutics Inc’s year-ago sales were $213.17MFor the next quarter, 12 analysts are estimating revenue of $194.19M. There is a high estimate of $259M for the next quarter, whereas the lowest estimate is $169M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.95B, while the lowest revenue estimate was $1.72B, resulting in an average revenue estimate of $1.8B. In the same quarter a year ago, actual revenue was $806.78MBased on 14 analysts’ estimates, the company’s revenue will be $980.18M in the next fiscal year. The high estimate is $1.18B and the low estimate is $804.3M.
